Outcomes: PFS benefit and relapse reduction

In this week's episode we'll learn about how by combining PET response with circulating tumor DNA, or  ctDNA, in newly treated patients with follicular lymphoma, investigators identify those patients likely to progress within 24 months of initial treatment, also known as POD24. After that: Immune hotspots in aplastic anemia. These newly identified hotspots potentially represent sites in the bone marrow where the active immune response takes place, driving the destruction of hematopoietic stem and progenitor cells. Finally, allogeneic transplantation for Hodgkin lymphoma in the checkpoint inhibitor era. In a large, retrospective study, patients with prior checkpoint inhibitor exposure had remarkable outcomes, particularly when post-transplant cyclophosphamide was used.

Featured Articles: 

• Combined PET and ctDNA response as predictors of POD24 for follicular lymphoma after first-line induction treatment
• Imaging Mass Cytometry Reveals the Order of Events in the Pathogenesis of Immune-Mediated Aplastic Anemia
• Outcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis